Skip to main content
RM

Rebel Medicine

The startup develops a long-acting injectable local anesthetic that provides 96-120 hours of analgesia post-surgery, significantly reducing the reliance on opioids. Additionally, it offers a shear-thinning gel for delivering various active pharmaceutical ingredients, enabling pharmaceutical companies to enhance drug effectiveness while lowering costs.

Salt Lake City, United States12300+ followers
Updated 2 months ago

Funding

$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

AL
Funding rounds are not available yet.

Founders

Product

Problem

Post-operative pain management relies heavily on opioid-based medications, which carry significant risks of adverse events, prolonged hospital stays, and potential for dependence. Current local anesthetics often lack the duration needed to cover the most intense post-operative pain period, typically the first 72 hours.

Solution

Rebel Medicine is developing Alevatrix™, a long-acting, injectable formulation of the local anesthetic bupivacaine, designed to provide sustained pain relief for 72-96 hours post-surgery, reducing or eliminating the need for opioids. Alevatrix™ utilizes a proprietary injectable gel technology and is packaged in a ready-to-use, prefilled syringe suitable for both regional anesthesia via nerve blocks and local anesthesia via instillation. By controlling pain locally, Alevatrix™ aims to improve patient outcomes and lower healthcare costs associated with opioid use. Rebel Medicine is also developing Alevaderm, a combination wound dressing that delivers local anesthetics for up to 7 days, combining moist wound healing and prolonged analgesia to address the needs of patients with painful wounds.

Target Audience

The primary target audience includes surgical patients requiring post-operative pain management, clinicians seeking non-opioid pain relief options, and patients with painful wounds such as abrasions, second-degree burns, and split-thickness skin graft donor sites.

Features

  • Alevatrix™: Extended-release bupivacaine gel for post-operative pain management
  • Alevatrix™: Provides 72-96 hours of local pain control, reducing the need for opioids
  • Alevatrix™: Ready-to-use, prefilled syringe for regional and local anesthesia
  • Alevatrix™: Utilizes a proprietary injectable gel technology
  • Alevaderm: Combination wound dressing delivering local anesthetics for up to 7 days
  • Alevaderm: Promotes moist wound healing for painful partial-thickness wounds
  • Alevaderm: Designed to function as a temporary epidermal replacement
This profile is AI-generated and may contain inaccuracies.